Epysqli is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Epysqli is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameEpysqli
Authorized genericeculizumab-aagh
Regular genericeculizumab-aagh
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Epysqli?
The original
–
–

Brand nameThe maker’s card

EPYSQLI Savings Program

Savings card from Teva Pharmaceuticals

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

Sign up on epysqli.com 

Or call 1-844-478-1644.

In the maker’s words

“Enroll in the EPYSQLI Savings Program to receive cost support and pay as little as $0 for your medicine…”

From the maker’s offer on epysqli.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Epysqli itself, from the same company, sold without the brand name, and usually for less. For now Epysqli is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Epysqli is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

EPYSQLI is a complement inhibitor indicated for:

  • the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
  • the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. Limitation of Use EPYSQLI is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
  • the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
  • the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Source: the FDA label for Epysqli (Teva Pharmaceuticals USA, Inc.), July 6, 2026. Full label on DailyMed 

Good to know